InvestSMART

Medical Developments International Limited (ASX: MVP) - Share Price

Current share price for MVP : $0.410 0.005 (1.20%)+

Medical Developments International Limited (MVP), an ASX-listed company, is a Company engaged in delivering emergency medical solutions. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine and for analgesia during short surgical procedures.

MVP General Information +

ASX Code MVP
Website http://www.medicaldev.com
Industry/Sector Pharmaceuticals
Market Cap ($M) 46
MVP Share Price $0.410
Day High $0.415
Day Low $0.400
Last Close $0.415
MVP Share Price Movement $0.01 ( 1.20% )
Prices as at 16:40, 22 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Medical Developments International Limited (MVP) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield
Result 100% 5 Mar 2020 17 Apr 2020 - - -
HFResult 100% 3 Sep 2019 4 Oct 2019 - - -
Result 100% 7 Mar 2019 17 Apr 2019 - - -

See all dividends from Medical Developments International Limited (MVP) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Medical Developments International Limited (MVP) price-sensitive announcements

MVP - Appendix 4C and Quarterly Activity Report 31 March 2026
Medical Developments International (MVP) released its Appendix 4C and Quarterly Activity R
Medical Developments International Limited (MVP)
24 Apr 2026 | 8:58 AM
MVP - FY26 Half Year Announcement
Medical Developments International Limited (MVP) reported its FY26 Half Year results, high
Medical Developments International Limited (MVP)
19 Feb 2026 | 8:55 AM
MVP - FY26 Half Year Presentation
Medical Developments International Limited (MVP) presented its FY26 Half Year Results, emp
Medical Developments International Limited (MVP)
19 Feb 2026 | 8:54 AM
MVP - FY26 Half Year Report (including Appendix 4D)
Medical Developments International Limited's FY26 Half Year Report highlights a $0.2 milli
Medical Developments International Limited (MVP)
19 Feb 2026 | 8:54 AM

Medical Developments International Limited (MVP) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Medical Developments International Limited (MVP)
ORDINARY FULLY PAID
Health Care $46 Becoming a substantial holder 3 Jun 2026 3:23PM $0.375 $0.410 risen by 9.33%
Medical Developments International Limited (MVP)
ORDINARY FULLY PAID
Health Care $46 Change in substantial holding 2 Jun 2026 1:13PM $0.375 $0.410 risen by 9.33%
Medical Developments International Limited (MVP)
ORDINARY FULLY PAID
Health Care $46 Notification of cessation of securities - MVP 14 May 2026 1:47PM $0.435 $0.410 fallen by 5.75%
Medical Developments International Limited (MVP)
ORDINARY FULLY PAID
Health Care $46 Appendix 4C and Quarterly Activity Report 31 March 2026 24 Apr 2026 8:58AM $0.385 $0.410 risen by 6.49%
Medical Developments International Limited (MVP)
ORDINARY FULLY PAID
Health Care $46 Notification of cessation of securities - MVP 20 Apr 2026 12:19PM $0.380 $0.410 risen by 7.89%
Medical Developments International Limited (MVP)
ORDINARY FULLY PAID
Health Care $46 Change in substantial holding 16 Apr 2026 5:03PM $0.395 $0.410 risen by 3.80%

MVP Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A $0.09 $0.10 -100.30% 565.40 0.00 0.00% 0.0%
2024A -$24.62 -$27.80 34.80% 0.00 0.00 0.00% 0.0%
2023A -$17.83 -$20.60 26.10% 0.00 0.00 0.00% 0.0%

MVP Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
Clarity Pharmaceuticals Ltd (CU6) $809M 0.3002 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Medical Developments International Limited (MVP) $47M -1.0032 0.0000 0.0000 461.1111 0.0000 0.0000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals Limited (NEU) $1,615M -0.7857 0.0743 1.2000 54.7486 50.9600 23.1636 0.00% 0.00% 0.00%

MVP Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.68 455.60 0.84 0.00
Market 0.29 13.20 1.17 0.67
Sector 0.43 26.20 2.49 2.38

MVP Directors

Name Position Start Date
Mr Leon Hoare Non-Executive Director 27 Sep 2013
Ms Christine Emmanuel-Donnelly Non-Executive Director 26 May 2020
Mr Paul Townsend Non-Executive Director 30 May 2025
Dr Russell Basser Non-Executive Director 31 Aug 2023
Mr Mark Fladrich Non-Executive Director, Non-Executive Chairman 1 Apr 2025

Medical Developments International Limited (MVP) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
30 Oct 2025 BASSER, Russell Buy Direct Shares 40,000 $0.706 $28,227.000
30 Sep 2025 FLADRICH, Mark Buy Direct Shares 62,858 $0.710 $44,629.000
22 Sep 2025 TOWNSEND, Paul Buy Direct Shares 25,000 $0.671 $16,785.310

See all changes in directors' interest & trades for Medical Developments International Limited (MVP) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

MVP Management

Name Position
Brent MacGregor Chief Executive Officer
A James Chief Financial Officer
Tara Eaton Company Secretary,General Counsel

MVP Calendar of Events

Date Event
18 February 2027 Report (Interim)
07 September 2026 Report (Annual)
20 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.